Allergy Therapeutics plc has disclosed a public dealing disclosure by Panmure Gordon (UK) Limited, an exempt principal trader with recognized intermediary status. The disclosure is made in accordance with Rule 8.5 of the Takeover Code. The form provides key information about the dealings undertaken by Panmure Gordon in relation to Allergy Therapeutics plc.

The form states that Panmure Gordon made purchases and sales of the 0.1p ordinary shares of Allergy Therapeutics plc. The total number of securities purchased was 0, and the total number of securities sold was 56,498. The highest price per unit received for the sales was 0.028, while the lowest price per unit received was 0.0266.

No cash-settled derivative transactions or stock-settled derivative transactions were disclosed in the form.

The form also states that there are no indemnity or option arrangements, agreements, or understandings relating to relevant securities that may be an inducement to deal or refrain from dealing.

The disclosure was made on August 30, 2023, and the contact person for further information is Freddie Wooding, with a telephone number of +44 (0)20 7886 2969.

It is important to note that the information provided in the form is specific to the dealings undertaken by Panmure Gordon and does not provide any additional information about Allergy Therapeutics plc or its operations.